FDA PANEL OKs CERVICAL CANCER VACCINE

JUNE 01, 2006

Merck's Gardasil, a vaccine that blocks viruses that cause most cervical cancers, has been given the green light by an FDA advisory committee. The panel voted 13 to 0, stating that the vaccine was safe and effective and should be approved.The FDA, which usually follows the panel's recommendation, is expected to make a decision this month.

The vaccine is indicated for the treatment of sexually transmitted diseases, particularly 4 strains of human papillomavirus that can cause cervical cancer and genital warts. A Merck official said that the vaccine could be recommended for women aged 9 to 26, but it would work best for individuals who have not yet had sex. The expected cost of the vaccine is $300 to $500 (for 3 injections given over 6 months).




SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.